ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-6.07 Insider Own0.60% Shs Outstand41.42M Perf Week8.97%
Market Cap793.13M Forward P/E- EPS next Y-2.72 Insider Trans0.00% Shs Float39.98M Perf Month44.07%
Income-194.10M PEG- EPS next Q-0.17 Inst Own80.60% Short Float / Ratio8.82% / 4.77 Perf Quarter29.73%
Sales300.90M P/S2.64 EPS this Y65.60% Inst Trans15.42% Short Interest3.53M Perf Half Y19.06%
Book/sh3.14 P/B6.06 EPS next Y-141.50% ROA39.50% Target Price22.50 Perf Year31.65%
Cash/sh11.77 P/C1.62 EPS next 5Y-8.89% ROE-100.90% 52W Range10.81 - 21.25 Perf YTD58.04%
Dividend- P/FCF- EPS past 5Y29.70% ROI-11.00% 52W High-8.00% Beta1.28
Dividend %- Quick Ratio2.50 Sales past 5Y70.90% Gross Margin99.30% 52W Low80.85% ATR0.86
Employees437 Current Ratio2.50 Sales Q/Q16.50% Oper. Margin-54.10% RSI (14)72.23 Volatility3.73% 5.93%
OptionableYes Debt/Eq3.09 EPS Q/Q-468.60% Profit Margin68.60% Rel Volume0.52 Prev Close19.02
ShortableYes LT Debt/Eq2.07 EarningsNov 01 BMO Payout0.00% Avg Volume738.66K Price19.55
Recom2.70 SMA2016.31% SMA5030.39% SMA20026.81% Volume87,062 Change2.79%
Jan-11-22Upgrade B. Riley Securities Neutral → Buy $25 → $30
Aug-20-21Downgrade Goldman Neutral → Sell $17 → $10
May-25-21Downgrade B. Riley Securities Buy → Neutral $18
Mar-12-21Upgrade H.C. Wainwright Sell → Neutral $21
Feb-23-21Downgrade H.C. Wainwright Neutral → Sell $25
Jan-15-21Downgrade BofA Securities Neutral → Underperform $40 → $27
Dec-21-20Downgrade Jefferies Buy → Hold $30
Nov-10-20Upgrade Robert W. Baird Neutral → Outperform $52
Nov-10-20Upgrade Raymond James Mkt Perform → Outperform $60
Jul-31-20Initiated Piper Sandler Overweight $82
Show Previous Ratings
Jan-25-23 04:06PM
Jan-20-23 09:55AM
09:53AM
Jan-19-23 08:00AM
Jan-13-23 11:41AM
08:00AM Loading…
Jan-05-23 08:00AM
Jan-04-23 09:00AM
Dec-23-22 07:50AM
Dec-20-22 11:15AM
Dec-19-22 04:08PM
01:33PM
Dec-08-22 06:00PM
Dec-05-22 08:29AM
Dec-01-22 11:31AM
Nov-22-22 08:00AM
07:37AM Loading…
Nov-08-22 07:37AM
Nov-07-22 06:55PM
08:00AM
Nov-06-22 08:00AM
Nov-02-22 11:38AM
Nov-01-22 12:09PM
08:15AM
07:00AM
Oct-31-22 04:05PM
Oct-30-22 10:40AM
Oct-26-22 10:01AM
Oct-25-22 08:00AM
Oct-12-22 08:40AM
08:00AM
Oct-06-22 10:28AM
09:24AM Loading…
Oct-02-22 09:24AM
Sep-30-22 04:08PM
09:44AM
07:55AM
Sep-26-22 10:46AM
Sep-21-22 11:33AM
07:30AM
Sep-20-22 12:45PM
09:03AM
Sep-14-22 01:35PM
Sep-08-22 11:30AM
Sep-07-22 08:00AM
Sep-02-22 11:31AM
Aug-29-22 10:49AM
08:00AM
Aug-19-22 07:30AM
Aug-18-22 10:20AM
08:00AM
Aug-17-22 10:16AM
Aug-05-22 04:31AM
04:27AM
Aug-04-22 09:18AM
Aug-03-22 01:05PM
08:30AM
08:25AM
07:00AM
Aug-01-22 10:01AM
Jul-27-22 08:00AM
Jul-19-22 09:26AM
Jul-18-22 06:00PM
Jul-08-22 12:53PM
11:12AM
11:12AM
Jul-07-22 11:23AM
08:06AM
07:30AM
Jul-01-22 04:01PM
Jun-24-22 08:08AM
Jun-21-22 07:30AM
Jun-07-22 10:06AM
Jun-06-22 02:45PM
06:30AM
Jun-03-22 07:30AM
May-13-22 08:42AM
May-12-22 09:11AM
May-11-22 08:00AM
May-10-22 06:16AM
May-09-22 02:15PM
May-06-22 08:25AM
07:00AM
May-05-22 04:21PM
08:25AM
07:17AM
May-04-22 06:15PM
May-02-22 08:00AM
Apr-27-22 05:06AM
Apr-22-22 11:36AM
Apr-07-22 05:15PM
Apr-01-22 11:30AM
05:13AM
Mar-03-22 11:03AM
Mar-02-22 08:25AM
07:02AM
07:00AM
Feb-23-22 08:49AM
Feb-17-22 03:03PM
Feb-15-22 11:02AM
Feb-10-22 03:36PM
Jan-29-22 05:51AM
Jan-18-22 01:38PM
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.